Background: Induction chemotherapy for patients with head and neck cancer is widely performed, and several advantages of induction chemotherapy have been reported. However, there is currently insufficient evidence to strongly recommend induction chemotherapy. In this study, we analyzed the outcomes for patients treated with induction chemotherapy and subsequent definitive treatments. Methods: Operable patients with untreated oropharyngeal, hypopharyngeal and laryngeal squamous cell carcinoma treated with induction chemotherapy were included in this retrospective study. We conducted induction chemotherapy using docetaxel, cisplatin and 5-fluorouracil and performed subsequent surgical treatment or radiotherapy according to the response to induction chemotherapy. Results: A total of 65 patients were included in this study, and 50 patients (76.9%) had Stage IV tumors. The response to induction chemotherapy was CR in two patients, PR in 55 patients, and SD in eight patients. The subsequent definitive treatment was radiotherapy in 60 patients, and surgery in five patients. The 3-year overall survival rates for patients who received radiotherapy and surgery were 88.4% and 75.0%, respectively (P = 0.30). The 3-year disease-free survival rates for patients who received radiotherapy and surgery were 68.0% and 0%, respectively (P = 0.01). The 3-year laryngeal dysfunction free survival rates for patients who received RT and surgery were 77.8% and 0%, respectively (P < 0.01). Conclusions: We achieved favorable survival outcomes and high larynx preservation rates. Our results suggest that induction chemotherapy using TPF regimen is one of the optimal treatment strategies when treating head and neck cancers. Further prospective studies with a larger cohort are required to confirm our findings.
Introduction
Most head and neck squamous cell carcinomas (HNSCC) are locally or locoregionally advanced at presentation. Surgery and/or radiotherapy are commonly applied as definitive therapies, often in combination with chemotherapy (1) . Platinum-based concurrent chemoradiotherapy (CRT) has become a popular approach, and induction chemotherapy (ICT) is also performed for locally advanced cancer when the goal is to preserve the larynx (2) (3) (4) . In cases where the patient receives ICT, definitive treatment modality is decided according to the response to ICT (4). Yanagi et al. (5) evaluated the propriety of chemo-selection at Nagoya City University Hospital, and demonstrated that responders to ICT appear to be good candidates for definitive organ-preserving treatment.
In the present study, we analyzed the toxicities, completion ratio, survival outcomes and larynx preservation rates for patients treated with ICT and subsequent definitive treatments, and confirmed their high completion ratio and good survival outcomes.
Materials and methods

Patients
Operable patients with untreated oropharyngeal, hypopharyngeal and laryngeal squamous cell carcinoma treated with ICT at Nagoya City University Hospital between December 2003 and January 2016 were included in this retrospective study. This study was approved in the ethical committee at our institute (management number: 60 160 197). We applied ICT using docetaxel, cisplatin and 5-fluorouracil (5-FU) to patients deemed suitable according to the following inclusion criteria: aged under 75 years, Eastern Cooperative Oncology Group (ECOG) Performance Status Grade 0-2, and having no deficiency in renal, hepatic, bone-marrow or cognitive function. Sixty-five patients with tumors at Stages II-IV were eligible for analysis. The TNM classification criteria of the International Union Against Cancer (seventh edition) were used.
Chemo-selection
In order to promote organ preservation, we performed ICT as initial treatment for all patients then made a recommendation to undergo radiation therapy (with/without concurrent chemotherapy) in the responders (patients exhibiting a complete or partial response evaluated using the Response Evaluation Criteria In Solid Tumors version 1.1; RECIST1.1). However, the final decision of treatment modality following ICT was made according not only to the response but also to a physician's assessment, comorbidities and the patient's wishes.
Induction chemotherapy
The TPF regimen consisted of 5 
Concurrent chemoradiotherapy
Radiotherapy (RT) or concurrent chemoradiotherapy (CRT) was performed for 60 patients after ICT. CRT consisted of the administration of docetaxel at a dose of 10 mg/m 2 for 2-6 cycles every week in 27 patients. Six patients received weekly carboplatin treatment (area under the curve from pharmacokinetic measurement; AUC was targeted to 1). Seventeen patients received bioradiotherapy (BRT) consisting of a loading dose of cetuximab 400 mg/m 2 on Day 1 of the week preceding RT and thereafter a weekly dose of 250 mg/m 2 during RT (6). The remaining 10 patients received RT alone. We mostly chose cetuximab after May 2013 according to TREMPLIN trial. However, we chose RT alone for patients with comorbidity such as pulmonary disease which would be associated with an increased risk of complication. Before May 2013, we mostly chose docetaxel, and chosen carboplatin for patients who showed complication owing to docetaxel during ICT. We chose RT alone for aged patients (>70 years old) or patients whose PS were 1 or 2. We irradiated to primary site and neck region with enough dose determined by radiation oncologists. In case the patient had hypopharyngeal cancer, we irradiated to retropharyngeal region with enough prophylactic dose.
Surgical treatment
Surgical treatments with curative intent were recommended for the non-responders to ICT (patients exhibiting stable or progressive disease, evaluated using RECIST1.1). The majority of patients underwent total laryngectomy or total pharyngolaryngectomy and bilateral modified radical neck dissection. When residual neck disease was suspected after definitive RT, we performed selective neck dissection 2-4 weeks after the imaging examinations. When a residual primary tumor was suspected after definitive RT, we performed a biopsy and salvage surgery such as total pharyngolaryngectomy for the primary site.
Statistical analysis
All events were measured from the date of completion of treatment for the original disease to the date of their occurrence or the date of the last follow-up visit, whichever occurred first. Overall survival (OS) was defined as the period until the event of death from any cause. Diseasefree survival (DFS) was defined as the period until the event of any of local, regional or distant recurrence or death from any cause. Laryngectomy free survival (LFS) was defined as the period until the event of total laryngectomy or death from any cause. Laryngeal dysfunction free survival (LDFFS) was defined according to the international consensus and included the presence of natural speech, the absence of a tracheostomy, the absence of use of a feeding tube for two or more years after the end of treatment, and the absence of recurring pneumonia that required hospitalization within the preceding 12 months (3). Curves describing the OS, DFS, LFS and LDFFS were generated using the Kaplan-Meier method. The log-rank test was used to test the statistical significance of the differences between the actuarial curves.
Results were considered statistically significant if the probability that the null hypothesis was true was <0.05. All statistical analyses were performed with EZR version 1.33 (Saitama Medical Center, Jichi Medical University, Saitama, Japan), which is a graphical user interface for R (The R Foundation for Statistical Computing, Vienna, Austria). More precisely, it is a modified version of R commander (version 1.6-3) designed to add statistical functions frequently used in biostatistics (7).
Results
Patients
A total of 65 patients were included in this retrospective study. The median follow-up time was 30 months. The majority were male (58 of 65; 89%), and the mean age was 64 years old (patients ranged from 40 to 77 years old Table 1 .
Induction chemotherapy
The number of patients who received three cycles of ICT was 47 (72%), 13 patients (20%) received two cycles, and the remaining five patients (8%) received one cycle. A complete case was defined as having received two or three cycles of ICT, and the completion rate was 92%. The toxicity of ICT was evaluated using the Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. The most frequent adverse event was neutropenia. Twenty six patients (41%) displayed Grade 3 neutropenia, and 33 patients (52%) displayed Grade 4 neutropenia. Febrile neutropenia occurred in 12 patients (19%). Grade 3 or 4 adverse events are shown in Table 2 . After ICT, we evaluated the response to ICT using RESIST 1.1. The response was CR in two patients (3%), PR in 55 patients (85%), and SD in eight patients (12%). The definitive treatment after ICT was RT in 60 patients (92.3%), and surgery in five patients (7.7%). The response to ICT was significantly worse in patients who received surgery for definitive treatment (Fisher's exact test P = 0.01).
Radiotherapy
The median dose of definitive RT was 66 Gy, and 24 patients (40.0%) received Intensity Modulated Radiation Therapy (IMRT). No one who received definitive RT dropped out of the treatment during RT. In patients who received surgery after ICT, two of five patients received post-operative radiation therapy (PORT) and the doses in these two cases were 61.4 Gy (as IMRT) and 60.0 Gy.
Surgical treatment
Five patients showed poor response to ICT and received surgical treatment for primary site and neck disease if necessary. Of the five patients who received surgical treatment, one patient had oropharyngeal carcinoma and underwent local resection, two patients had hypopharyngeal carcinoma and underwent total pharyngolaryngectomy, and two patients had laryngeal carcinoma and underwent total laryngectomy. For the treatment of neck disease, three patients underwent bilateral modified radical neck dissection, one patient underwent ipsilateral modified radical neck dissection, and one patient underwent surgery only for the primary site. A summary for these five patients is shown in Table 3 .
Survival
The 3-year overall and disease-free survival rates for all patients were 87.2% and 63.4% respectively. The 3-year overall survival rates for patients with oropharyngeal, hypopharyngeal and laryngeal carcinoma were 71.5%, 95.8% and 100%, respectively (P = 0.30). The 3-year disease-free survival rates for patients with oropharyngeal, hypopharyngeal and laryngeal carcinoma were 68.3%, 53.7% and 81.5%, respectively (P = 0.20). The 3-year overall survival rates for patients who received RT and surgery were 88.4% and 75.0%, respectively (P = 0.30; Fig. 1A) . The 3-year disease-free survival rates for patients who received RT and surgery were 68.0% and 0%, respectively (P = 0.01; Fig. 1B ).
Larynx preservation
The 3-year laryngectomy free and laryngeal dysfunction free survival rates for all patients were 80.5% and 73.3%, respectively. The 3-year laryngectomy free survival rates for patients who received RT and surgery were 85.6% and 0%, respectively (P < 0.01; Fig. 2A) . The 3-year laryngeal dysfunction free survival rates for patients who received RT and surgery were 77.8% and 0%, respectively (P < 0.01; Fig. 2B ). Three patients remained tracheostomy, two patients required feeding tube, and two patients both remained tracheostomy and required feeding tube.
Recurrence Twenty-one patients experienced tumor recurrence or had residual tumors during follow-up. The site of recurrent or residual tumor was local in 15 patients, regional in seven patients, and distant in three patients. Metastasis to the lateral retropharyngeal (Rouviere) lymph node after initial treatment did not occur, with the exception of two cases where tumors had been present prior to ICT.
Concurrent chemoradiotherapy
We evaluated the benefit of utilizing concurrent chemotherapy combined with RT after ICT. The 3-year overall survival rates for patients who received Cetuximab plus RT, others (docetaxel or carboplatin) plus RT, and RT alone were 93.8%, 85.9% and 100%, respectively (P = 0.42; Fig. 3A ). The 2-year disease-free survival rates for patients who received Cetuximab plus RT, others plus RT and RT alone were 54.2%, 74.8% and 66.7%, respectively (P = 0.82; Fig. 3B ). The 3-year laryngectomy free survival rates for patients who received Cetuximab plus RT, others plus RT and RT alone were 81.2%, 86.0% and 100%, respectively (P = 0.15; Fig. 4A ). The 3-year laryngeal dysfunction free survival rates for patients who received Cetuximab plus RT, others plus RT and RT alone were 70.6%, 83.1% and 77.8%, respectively (P = 0.35; Fig 4B) .
Discussion
The present study demonstrated favorable survival rates and organpreservation rates, with 3-year OS and DFS rates of 87.2% and 63.4%, and 3-year LFS and LDFFS rates of 80.5% and 73.3%, respectively. These results were comparable to those of previous studies (3, 4, 6, 8, 9) . The favorable results of the present study were mainly due to the high completion rates of treatment. The completion rate of ICT was 92% and that of following definitive RT was 100%. Unfortunately, ICT using TPF regimen may be associated with severe side effects, especially amongst Asian individuals (10). Wang et al. proposed a dose-modified TPF regimen (11) . In our study, we experienced Grade 3 or 4 adverse events in some cases. However, we performed ICT using TPF regimen with the same dose as the TAX323 study, and achieved a high completion rate and The responses to ICT were evaluated according to the Response Evaluation Criteria In Solid Tumors version 1.1. ICT, induction chemotherapy; SD, stable disease; PR, partial response; TPL, total pharyngolaryngectomy; TL, total laryngectomy; mRND, modified radical neck dissection. favorable survival rates. It is important to have appropriate criteria when considering the use of ICT and to keep in mind adverse effects in order to design a treatment schedule with the minimum of critical side effects. Our inclusion criteria were: age under 75 years, ECOG Performance Status Grade 0-2, having no deficiency of renal, hepatic, bone-marrow or cognitive function. Additionally, in order to avoid adverse events, close attention was paid to the following: (1) We used granulocyte colony stimulating factor (G-CSF) when neutropenia occurred, mostly during the period between Day 6 and Day 15 (data not shown). We also administered broad-spectrum antibiotics such as cefepime to patients with febrile neutropenia. (2) After administering 5-FU, some patients still had dysphagia and required intravenous hydration. (3) Diarrhea mostly occurred between 10 and 15 days after ICT (data not shown), and loperamide hydrochloride was shown to be effective in treating this. In severe cases, we forbade oral intake and administered total parenteral nutrition through a central venous catheter. (4) The presence of alopecia indicates that the ICT is still affecting the body. Therefore, we began the next cycle of ICT after alopecia stopped occurring. We believe that the high completion rate and favorable outcomes in the present study were due to these inclusion criteria and careful treatment.
Another reason for favorable outcomes may be the low incidence rate of retropharyngeal lymph node metastasis. In some previous studies, retropharyngeal lymph node metastases were correlated with poor prognosis (12, 13) . In the present study, we experienced no retropharyngeal lymph node metastasis after initial treatment, except for residual tumors in two cases. We concluded that this low incidence rate might be due to the treatment strategy including ICT using TPF regimen.
The superiority of TPF to cisplatin plus 5-FU (PF) was demonstrated in TAX323, 324 trials (14, 15) . However, some investigators raised questions about this conclusion (16) , indicating the limitation of the long-term results of the TAX324 trial (17) . When the results of previous studies were considered, it could be seen that TPF regimen did not necessarily improve the overall survival rate compared with PF regimen. On the other hand, the superiority of TPF with regards to larynx preservation and rate of complete remission (CR) was clearly indicated. TPF has the advantage in cases where a clinician is mainly focused on larynx preservation. However, it is important to consider the risk of local recurrence and dysfunctional larynx (also known as 'frozen larynx') (18) in cases where larynx preservation is prioritized. Therefore, it is important to consider the balance of outcomes when performing any treatment. In the present study, we achieved a favorable survival rate whilst maintaining an acceptable functional larynx preservation rate. We believe our treatment strategy was optimal for patients.
Previous investigators performed ICT and selected following treatment modality according to the response to ICT -so called 'chemoselection' (4). Ijichi et al. (19) and Nakata et al. (20) selected therapeutic treatment with alternating chemoradiotherapy using PF regimen for patients with laryngeal carcinoma, and reported that alternating chemoradiotherapy treatment might enable larynx preservation. Matsuzuka et al. (21) performed ICT with PF followed by alternating chemoradiotherapy with TPF or surgery for patients with hypopharyngeal carcinoma. They also performed chemo-selection with ICT, and demonstrated that their treatment strategy could be safe and have enough impact to control hypopharyngeal cancer in good responders. Yanagi et al. (5) evaluated the propriety of chemoselection at Nagoya City University Hospital, and demonstrated that responders to ICT appear to be good candidates for definitive organ-preserving treatment. In accordance with these previous studies, we designed our treatment strategy to include chemo-selection with TPF regimen and achieved highly satisfactory outcomes. Therefore, we concluded that chemo-selection could be one of the validated treatment strategies for patients with pharyngeal and laryngeal carcinoma, especially in cases where organ preservation is required.
We performed radiotherapy and concurrent cetuximab treatment (BRT) after ICT according to the results of the TREMPLIN study (6) . This previous study demonstrated that the survival outcomes for patients received BRT was comparable to that for patients received cisplatin plus RT. However, this study also demonstrated that there is no evidence that one treatment was superior to the other or could improve the outcome reported with ICT followed by RT alone (3) . In the present study, we could not find the advantage of adding concurrent chemotherapy or biotherapy to RT after ICT. However, the number of patients in each group was relatively small if we compare the outcomes between patients who received RT alone, BRT or RT plus other chemotherapy after ICT. Furthermore, the survival outcomes for patients receiving RT alone after ICT were already favorable, therefore the advantage of adding concurrent chemotherapy or biotherapy might be undetectable.
The present study was retrospective and utilized a relatively small cohort, so further studies that are prospective and have a larger cohort are required to confirm our findings.
Conclusion
We evaluated the survival outcomes, larynx preservation rate, and toxicities for 65 patients who received ICT treatment using TPF regimen at Nagoya City University Hospital. We achieved favorable survival outcomes and a high larynx preservation rate, and concluded that these positive outcomes may be due to the high completion rate of these series of treatments. Our results suggest that ICT using TPF regimen is one of the optimal treatment strategies for patients with HNSCC, if we use appropriate selection criteria and pay close attention to any side effects. Further studies that are prospective and utilize a larger cohort are required to confirm our findings.
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